Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Fibrosis, Ophthalmic and Immunosuppression Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TGF/TGFB2 drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Ligand (TGFB2) | TGFB2 Active Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. Also available in Latent LAP complex. | View TGFB2 Products |
| Latent Complex | TGFB2-LAP Complex. Latent form for activation mechanism studies. Native glycosylation. | View TGFB2 Products |
| Gene Delivery | TGF/TGFB2 Promise-ORF / Lentivirus. Full-length ORF for stable cell line generation. | View TGFB2 Products |
| Benchmark Ab | Anti-TGF/TGFB2 Benchmark Antibody (Neutralizing). Recombinant positive control for assay standardization and comparative binding. | View TGFB2 Products |
| Validator (siRNA) | TGFB2 siRNA Set. For specific knockdown verification in cell-based assays and target validation. | View TGFB2 Products |
| Receptor Binding Pair | TGFBR2 ECD-Fc Fusion. For binding affinity and competition assays. High purity. | View TGFBR2 Products |
| Isoform Control 1 | TGFB1 Active Protein. Critical for isoform-specificity counter-screening to avoid pan-TGFB toxicity. | View TGFB1 Products |
| Isoform Control 2 | TGFB3 Active Protein. Required for comprehensive selectivity profiling across the TGFB family. | View TGFB3 Products |
| Related Synergistic Target | PD-L1. Primary synergistic target for bispecific/combination immunotherapies in the TME. | View PD-L1 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage |
|---|---|
| Isoform Specificity (TGFB1 vs TGFB2 vs TGFB3) | Complete TGFB homolog panel (active and latent) available, strictly verified by mass spec and sequence analysis. |
| Latent vs Active Form Discrimination | Both Mature (Active) and LAP-associated (Latent) TGFB2 proteins available with confirmed structural integrity. |
| Cross-species Preclinical Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity and matching theoretical MW. |
| Lack of Reliable Controls / False Positive Elimination | Clinical Benchmark Antibodies included for exact comparative binding, and sequence-verified siRNA for specificity confirmation. |
| Receptor Binding Competition | TGFBR2 ECD-Fc with verified binding activity to TGFB2 (SPR/BLI compatible). |
Live TGF/TGFB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TGF/TGFB2-targeted therapeutics is intensifying. In oncology, TGFB2 plays a profound role in driving immunosuppression, angiogenesis, and fibrosis within the tumor microenvironment (TME). Early-generation pan-TGFB inhibitors (e.g., Fresolimumab) faced systemic toxicity (cutaneous lesions, cardiotoxicity). The next wave of R&D is highly focused on isoform-specific targeting (particularly TGFB2) or condition-activated modalities. Major players are shifting focus toward bispecifics that combine localized TGFB2 blockade with PD-1/PD-L1 checkpoint inhibition, aiming to convert "cold" tumors to "hot." In ophthalmology, TGFB2 is implicated in diabetic macular edema (DME) and glaucoma; Rapta Therapeutics' pegleranib (anti-TGFB2 aptamer) leads this segment with strong clinical data. Fibrosis programs emphasize tissue-specific latent TGFB2 activation mechanisms for indications such as NASH and IPF.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antisense Oligo (ASO) | Isarna Therapeutics / Antisense Pharma | Glioblastoma, Solid Tumors | Target Knockdown Validation (Need siRNA controls & High-Purity Target for rescue) |
| Bispecific Fusion (anti-PD-L1/TGFBR2 Trap) | Merck KGaA, Hengrui, Biotheus | Advanced Solid Tumors, NSCLC | Heterodimer Validation (Need High-Purity TGFB2 and PD-L1 for dual-binding SPR) |
| Isoform-Selective mAb | Scholar Rock (Latent specific), Sanofi; Rapta Therapeutics (pegleranib) | Oncology, Fibrotic Diseases; Ophthalmic (DME, Glaucoma) | Selectivity Assay (Need precisely sequence-verified TGFB1, 2, and 3 active/latent proteins; conformational selectivity for latent/active) |
| Small Molecule Inhibitor | Novartis, Eli Lilly, Various | Refractory Cancers, Liver Fibrosis, NASH | Receptor Binding Assays (Need pure Ligand-Receptor pairs; TGFBR2-TGFB2 binding inhibition) |
| Aptamer (Anti-TGFB2) | Rapta Therapeutics (Pegleranib) | Ophthalmic Fibrosis (DME) | Latent/Active Conformation Binding (Conformational selectivity assays) |